Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764854 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2 study of End Stage Renal Disease and ESRD, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 3
- Study locations
NCT01764854 is a Phase 2 study of End Stage Renal Disease and ESRD that has completed, run by Ardelyx. The registered enrollment target is 88 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01764854, a Phase 2 study of End Stage Renal Disease and ESRD, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD1722 (in-patient)
- DRUG Placebo (in-patient)
- DRUG AZD1722 (out-patient)
Study Locations (3)
Arizona
- Southwest Clinical Research Institute - Tempe
Colorado
- Denver Nephrology - Denver
Minnesota
- DaVita Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764854
The ClinicalTrials.gov registry entry for NCT01764854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (89% lower). The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01764854 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01764854 about?
NCT01764854 is a clinical study titled "Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis". The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
What is the current status of trial NCT01764854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2013-01. Estimated completion is 2013-10.
What conditions does trial NCT01764854 study?
This clinical trial studies the following conditions: End Stage Renal Disease, ESRD, Chronic Kidney Disease Stage 5.
What interventions are being tested in trial NCT01764854?
The interventions under investigation include: Placebo (DRUG), AZD1722 (in-patient) (DRUG), Placebo (in-patient) (DRUG), AZD1722 (out-patient) (DRUG).
Who is sponsoring clinical trial NCT01764854?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01764854 being conducted?
This trial has 3 study locations across Arizona, Colorado, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.